Navigating The Future Of Hepatology Clinical Trials

In this discussion from the European Association for the Study of the Liver Congress (EASL), Novotech's Director of Therapeutic Strategy, Tom Hickey, joins Citeline’s Manufacturing Editor, Andrew Warmington, to explore the current and future state of hepatology clinical trials. Drawing on Novotech’s expertise as a global, full-service CRO, Tom highlights key trends, emerging opportunities, and persistent challenges that are shaping drug development in liver disease. This conversation offers timely perspectives for those looking to navigate the evolving clinical trial landscape in hepatology.